Savara Inc（简称Savara）宣布与Hercules Capital达成债务融资协议修订条款。根据新条款，一旦其核心药物Molbrevim获得美国食品药品监督管理局（FDA）批准，公司将获得最高7500万美元的追加债务融资额度。
此次协议修订强化了Savara的资本灵活性，为Molbrevim的商业化进程提供关键资金支持。通过结构化融资安排，公司可在新药获批后迅速激活额外资金流，加速市场布局。
该融资机制采用里程碑触发模式，将资金释放与监管审批直接挂钩。这种设计既降低了企业前期资金压力，又为投资方提供了明确的风险管控节点。
目前Molbrevim正处于FDA审评的关键阶段，此次融资条款的优化被视为Savara应对监管决策的重要战略部署。市场观察人士指出，该安排体现了专业医疗投资机构对创新药资产商业化前景的认可。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.